Chronic Sinusitis Clinical Trial
Official title:
A Clinical Study to Evaluate the Safety and Effectiveness of Novabel Bioabsorbable Steroid-releasing Stent for the Chronic Sinusitis
The goal of this clinical trial is to learn about the safety and effectiveness of Novabel bioabsorbable steroid-releasing stent in chronic sinusitis. The main questions it aims to answer are: - The safety of this device for the chronic sinusitis - The effectiveness of this device for the chronic sinusitis Participants will be implanted bioabsorbable steroid-releasing stents after FESS surgery. Participants will be asked to be back to the clinic for follow-up 14 days, 30 days, 90 days, 180 days and 360 days after procedure. Researchers will compare test device and marketed device to see if the safety and effectiveness between these two devices are non-inferior.
Status | Recruiting |
Enrollment | 93 |
Est. completion date | September 9, 2025 |
Est. primary completion date | September 9, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnose with CRS based on Chinese guidelines for diagnosis and treatment of chronic rhinosinusitis (2018), who were scheduled to undergo primary or revision bilateral ESS. - Have evidence of bilateral sinus based on computed tomographic (CT) scan (Lund-Mackay [L-M] score of <=3 on each side). - Can understand the purpose of this study and will to join and finish all the follow up according to the study. Sign the ICF. Exclusion Criteria: 1. Know history of allergy or intolerance to corticosteroids or mometasone furoate. 2. The subject has a known allergic reaction or contraindication to the device material and its degradation products (L-polylactic acid, racemic polylactic acid, lactide lactate, lactic acid). 3. Clinical evidence of cystic fibrosis, severe polyposis or sinonasal tumors. 4. Clinical evidence of acute bacterial sinusitis or suspicion of invasive fungal sinusitis. 5. Glaucoma, ocular hypertension, posterior subcapsular cataracts. 6. Known history of immune deficiency or concurrent condition requiring active chemotherapy and/or immunotherapy management for the disease. 7. Clinical evidence of disease or condition expected to compromise survival or ability to complete follow-up assessments during the 360 day follow-up period. 8. Current ESS including frontal sinus surgery is aborted for any reason. 9. Pregnant or lactating female 10. Investigator determination that the potential study subject is unable to comply with study procedures and/or follow-up, or provided informed consent. 11. Currently involved in another clinical study where that participation may conflict or interfere with the treatment, follow-up or results of the clinical study. |
Country | Name | City | State |
---|---|---|---|
China | Qilu Hospital of Shandong University | Jinan |
Lead Sponsor | Collaborator |
---|---|
Enlight Medical Technologies (Shanghai) Co., Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | adverse event rate | immediately after the procedure | ||
Primary | non reintervention rate | The need for postoperative interventions, medical and surgical, as determined based on review of video endoscopic findings by an independent blinded surgeon. | 30 days | |
Secondary | Lund-Kennedy score | Lund-Kennedy endoscopic scoring system based on polyps, oedema, discharge, scarring and crusting. from 0-2 is None/absent; mild; severe. | 30 days, 90 days, 180 days and 1 year | |
Secondary | Lund-Mackay score | Each side of sinus is graded separately: 0 (no abnormality); 1 (partial opacification); 2 (complete opacification). If there is no frontal sinus (aplasia), the score is 0. Scores were calculated based on the results of a paranasal sinus CT scan 1-3 mm axial slice thickness with coronal and sagittal reconstruction. Result: score 0-24. | 90 days | |
Secondary | VAS score | A 100mm VAS, ranging from 0 (no pain) to 100 (very severe pain), is used to measure pain intensity throughout the previous 24h. | 30 days, 90 days, 180 days and 1 year | |
Secondary | sinus panty rate | as determined based on review of video endoscopic findings by an independent blinded surgeon | 30 days, 90 days, 180 days and 1 year | |
Secondary | implantation successful rate | immediately after the procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02266810 -
Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus
|
Phase 3 | |
Completed |
NCT01706484 -
Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Chronic Rhinosinusitis
|
Phase 3 | |
Completed |
NCT01197612 -
Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis
|
Phase 3 | |
Completed |
NCT04163978 -
Nitric Oxide Releasing Sinus Irrigation (NOSi) to Treat Recalcitrant Chronic Rhinosinusitis (RCRS)
|
Phase 2 | |
Completed |
NCT04418622 -
Evolution of the Endonasal Microbiota in Patients With Chronic Rhinosinusitis
|
||
Not yet recruiting |
NCT06070311 -
Wound Healing After Endoscopic Sinus Surgery
|
N/A | |
Not yet recruiting |
NCT05454163 -
Post-radiotherapy Rhinosinusitis in Children
|
||
Withdrawn |
NCT01185808 -
Vitamin D Supplementation in Chronic Rhinosinusitis With Nasal Polyps
|
N/A | |
Completed |
NCT01700725 -
Gulf War Illness Nasal Irrigation Study
|
Phase 2 | |
Withdrawn |
NCT00671281 -
The Effect of Tranexamic Acid on Intraoperative and Post-Operative Bleeding in Functional Endoscopic Sinus Surgery
|
N/A | |
Completed |
NCT00447837 -
Evaluating SPRC-AB01 in Post-Surgical Subjects With Chronic Sinusitis
|
Phase 2 | |
Recruiting |
NCT04362501 -
Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
|
Phase 2 | |
Completed |
NCT05035654 -
LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)
|
Phase 2 | |
Completed |
NCT02562924 -
The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery
|
N/A | |
Completed |
NCT01007799 -
Vitamin D for Chronic Sinusitis
|
N/A | |
Completed |
NCT03358329 -
Safety Evaluation of Repeat Placement of the S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps (ENCORE)
|
Phase 3 | |
Withdrawn |
NCT02981017 -
Improvement of Outcomes in Draf III/Endoscopic Modified Lothrop Procedure
|
N/A | |
Completed |
NCT04041609 -
LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study)
|
Phase 2 | |
Recruiting |
NCT01854619 -
Photodynamic Therapy for the Treatment of Chronic Rhinosinusitis
|
N/A | |
Completed |
NCT00924404 -
Xylitol Versus Saline in Chronic Sinusitis
|
N/A |